iCeutica's proprietary SoluMatrix™ Fine Particle Technology fuels new product development and solves problems of bioavailability, variability, side effects and delivery of marketed or development-stage pharmaceuticals.
The SoluMatrix technology is a scaleable and cost-effective manufacturing process that can produce submicron-sized drug particles that are 10 to 200 times smaller than conventional drug particles. The particles generated using this technology, which both grinds the drug particles into a superfine powder and protects those submicron particles from subsequent agglomeration (or clumping together into big particles), comprise a single unit operation and can be manufactured into tablets, capsules and other dosage forms without further processing.
The SoluMatrix technology has been scaled up to commercial-scale and three products utilizing the technology have been approved by FDA and launched in the USA.
How SoluMatrix works
The SoluMatrix technology improves the performance of pharmaceuticals by dramatically changing how the drug dissolves and is absorbed. By making submicron-sized particles of a drug, it is possible to:
What SoluMatrix can do for your product
Using the SoluMatrix technology, iCeutica can transform development-stage or marketed pharmaceutical products in a number of clinically relevant and commercially important ways. For poorly soluble or highly variable products in development, we can ensure the product successfully progresses through clinical development and that the patient receives a consistent dose of the drug, with potentially less drug required and fewer side effects experienced. For marketed products, we can unleash improved performance and new intellectual property protection that extends the product lifecycle and profitability of the product.
Click here to view how the SoluMatrix technology improves non-steroidal anti-inflammatories (NSAIDs).